The week in health tech, explained in plain English.Get the free newsletter →
November 12, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

Revenue Cycle Becomes a CEO Priority at Top Health Systems

Revenue cycle management, long treated as a back-office function measured by denial rates, days in accounts receivable and cost to collect, has become a topic for the C-suite. According to Becker's Hospital Review, hospital and health system CEOs at Providence, Ascension and Tenet are now discussing revenue cycle as part of broader strategy, folding it into turnaround plans, payer negotiations, earnings calls and 2027 budgets.

The shift reflects financial pressure across the industry. As payer disputes intensify and margins stay thin, getting paid accurately and quickly is no longer just an operations problem. It is a lever executives use to stabilize systems and signal financial discipline to investors and lenders.

In practice, revenue cycle leaders say their function is gaining visibility and influence it did not have before. That means more investment in automation, tighter alignment with contract negotiations, and closer scrutiny of collections performance at the highest levels of the organization.

More in Finance

Finance

McLeod Health Operating Income Drops 9.7% as Costs Rise

McLeod Health's operating income fell 9.7% to $137.5 million in fiscal 2026 as expenses grew faster than its 8% revenue increase.

Why it matters: It shows that even revenue-growing health systems are losing margin as costs outpace reimbursement.

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.

Finance

Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ziltivekimab missed in the ZEUS cardiovascular trial, but cardiologists say the anti-inflammatory approach to heart disease remains valid.

Why it matters: Anti-inflammatory therapy is one of the biggest bets in cardiovascular medicine, and how the field reacts to a high-profile failure shapes billions in future R&D.